About the Study
This study is looking to see if the study drug, clofutriben, is safe, effective, and well tolerated for treating intractable type 2 diabetes. Clofutriben is an “investigational” drug because it has not been approved by the Food and Drug Administration (FDA).
If you qualify and choose to participate, there is an 80% chance you will receive the study drug and a 20% chance you will receive a placebo. A placebo is an inactive material that looks like the study drug but does not contain any active ingredient.
You will be on this study for about 37 weeks (approximately 9 months), which will include a screening period, a treatment period, and a follow-up period. The study will require approximately 7 in-clinic visits and 5 telephone visits. If you qualify and choose to participate, you may be compensated up to $2,418 for your study-related time and travel.
Your participation is entirely voluntary, and you can leave the study at any time. Participating in a research study may involve risks, discomforts, or inconveniences. These can include side effects from study procedures or medications (which may be mild, temporary, or, in rare cases, serious), discomfort from blood draws or examinations, loss of time, or the possibility that the study will not provide direct benefit to you.